Blood Biomarkers and 6- to 7-Year Childhood Outcomes Following Neonatal Encephalopathy.
Am J Perinatol
; 39(7): 732-749, 2022 05.
Article
em En
| MEDLINE
| ID: mdl-33038899
ABSTRACT
OBJECTIVE:
This study aimed to profile the cytokine/chemokine response from day 0 to 7 in infants (≥36 weeks of gestational age) with neonatal encephalopathy (NE) and to explore the association with long-term outcomes. STUDYDESIGN:
This was a secondary study of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network randomized controlled trial of whole body hypothermia for NE. Eligible infants with moderate-severe NE were randomized to cooling or normothermia. Blood spots were collected on days 0 to 1, 2 to 4, and 6 to 7. Twenty-four cytokines/chemokines were measured using a multiplex platform. Surviving infants underwent neurodevelopmental assessment at 6 to 7 years. Primary outcome was death or moderate-severe impairment defined by any of the following intelligence quotient <70, moderate-severe cerebral palsy (CP), blindness, hearing impairment, or epilepsy.RESULTS:
Cytokine blood spots were collected from 109 participants. In total 99 of 109 (91%) were assessed at 6 to 7 years; 54 of 99 (55%) developed death/impairment. Neonates who died or were impaired had lower early regulated upon activation normal T cell expressed and secreted (RANTES) and higher day 7 monocyte chemotactic protein (MCP)-1 levels than neonates who survived without impairment. Though TNF-α levels had no association with death/impairment, higher day 0 to 1 levels were observed among neonates who died/developed CP. On multiple regression analysis adjusted for center, treatment group, sex, race, and level of hypoxic ischemic encephalopathy, higher RANTES was inversely associated with death/impairment (odds ratio (OR) 0.31, 95% confidence interval [CI] 0.13-0.74), while day seven MCP-1 level was directly associated with death/impairment (OR 3.70, 95% CI 1.42-9.61). Targeted cytokine/chemokine levels demonstrated little variation with hypothermia treatment.CONCLUSION:
RANTES and MCP-1 levels in the first week of life may provide potential targets for future therapies among neonates with encephalopathy. KEY POINTS · Elevation of specific cytokines and chemokines in neonates with encephalopathy has been noted along with increased risk of neurodevelopmental impairment in infancy.. · Cytokine/chemokines at <7 days were assessed among neonates in a trial of hypothermia for HIE.. · Neonates who died or were impaired at 6 to 7 years following hypoxic-ischemic encephalopathy had lower RANTES and higher MCP-1 levels than those who survived without impairment..
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Paralisia Cerebral
/
Hipóxia-Isquemia Encefálica
/
Hipotermia Induzida
/
Doenças do Recém-Nascido
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Child
/
Humans
/
Newborn
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article